WCLC 2016 | Novel targets and biomarkers in mesothelioma

Michaela Kirschner, PhD of University Hospital Zurich, Switzerland discusses novel targets and biomarkers in malignant pleural mesothelioma. Dr Kirschner explains that it is difficult to treat mesothelioma; at present patients are treated with chemotherapy or surgical intervention but the majority of patients do not respond to these treatment options. Therefore, there is an urgent need to find new therapies. At the 2016 World Conference of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria, Dr Kirschner discussed talks on novel targets and biomarkers. Further, she talks about promising treatments currently under investigation in clinical trials, including a microRNA mimic (microRNA replacement therapy).